View Item 

Show simple item record

Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B‐cell lymphoma treated with CHOP‐based chemotherapy
dc.contributor.authorXiao, Daphne Y.
dc.contributor.authorLuo, Suhong
dc.contributor.authorO’Brian, Katiuscia
dc.contributor.authorGanti, Arun
dc.contributor.authorRiedell, Peter
dc.contributor.authorSanfilippo, Kristen M.
dc.contributor.authorLynch, Ryan C.
dc.contributor.authorLiu, Weijian
dc.contributor.authorCarson, Kenneth R.
dc.date.accessioned2016-10-17T21:18:45Z
dc.date.available2017-12-01T21:54:12Zen
dc.date.issued2016-10
dc.identifier.citationXiao, Daphne Y.; Luo, Suhong; O’Brian, Katiuscia; Ganti, Arun; Riedell, Peter; Sanfilippo, Kristen M.; Lynch, Ryan C.; Liu, Weijian; Carson, Kenneth R. (2016). "Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B‐cell lymphoma treated with CHOP‐based chemotherapy." American Journal of Hematology 91(10): 1002-1007.
dc.identifier.issn0361-8609
dc.identifier.issn1096-8652
dc.identifier.urihttps://hdl.handle.net/2027.42/134181
dc.publisherWiley Periodicals, Inc.
dc.publisherIARC Press
dc.titleImpact of sarcopenia on treatment tolerance in United States veterans with diffuse large B‐cell lymphoma treated with CHOP‐based chemotherapy
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biology
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.subject.hlbtoplevelScience
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134181/1/ajh24465_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134181/2/ajh24465.pdf
dc.identifier.doi10.1002/ajh.24465
dc.identifier.sourceAmerican Journal of Hematology
dc.identifier.citedreferenceKuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony‐stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 2007; 25: 3158 – 3167.
dc.identifier.citedreferenceAntoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose‐limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21: 1594 – 1598.
dc.identifier.citedreferenceMorton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 110: 695 – 708.
dc.identifier.citedreferenceZelenetz A. Non‐Hodgkin Lymphomas. Accessed from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
dc.identifier.citedreferenceRomano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases: Differing perspectives. J Clin Epidemiol 1993; 46: 1075 – 1079.
dc.identifier.citedreferenceSmith TJ, Bolke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015; 33: 3199 – 3212.
dc.identifier.citedreferenceThe International non‐Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non‐Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987 – 994.
dc.identifier.citedreferenceWHO Expert Commitee Physical status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1 – 452.
dc.identifier.citedreferenceDubois D, Dubois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863 – 871.
dc.identifier.citedreferenceHryniuk W, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990; 8: 1935 – 1937.
dc.identifier.citedreferenceLyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose‐intensity in aggressive non‐Hodgkin’s lymphoma: A nationwide study. J Clin Oncol 2004; 22: 4302 – 4311.
dc.identifier.citedreferenceMourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33: 997 – 1006.
dc.identifier.citedreferenceMartin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539 – 1547.
dc.identifier.citedreferenceCaram MV, Bellile EL, Englesbe MJ, et al. Sarcopenia is associated with autologous transplant‐related outcomes in patients with lymphoma. Leuk Lymphoma 2015; 56: 2855 – 2862.
dc.identifier.citedreferenceLyman G, Lyman C, Agboola O. Risk models for predicting chemotherapy‐induced neutropenia. Oncologist 2005; 10: 427 – 437.
dc.identifier.citedreferenceGanti A, Liu W, Luo S., et al. Impact of BMI on incidence of febrile neutropenia and treatment‐related mortality in United States veterans with diffuse large B‐cell lymphoma receiving R‐CHOP. Br J Haematol 2013; 167: 699 – 702.
dc.identifier.citedreferencePeyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R‐miniCHOP) in elderly patients older than 80 years with diffuse large B‐cell lymphoma: A multicentre, single‐arm, phase 2 trial. Lancet Oncol 2011; 12: 460 – 468.
dc.identifier.citedreferenceSoubeyran P, Fonck M, Blanc‐Bisson C, et al. Predictors of early death risk in older patients treated with first‐line chemotherapy for cancer. J Clin Oncol 2012; 30: 1829 – 1834.
dc.identifier.citedreferenceBahat G, Saka B, Tufan F, et al. Prevalence of sarcopenia and its association with functional and nutritional status among male residents in a nursing home in Turkey. Aging Male 2010; 13: 211 – 214.
dc.identifier.citedreferencePrado CMM, Maia YLM, Ormsbee M, et al. Assessment of nutritional status in cancer – The relationship between body composition and pharmacokinetics. Anticancer Agents Med Chem 2013; 13: 1197 – 1203.
dc.identifier.citedreferenceCosolo W, Morgan D, Seeman E, et al. Lean body mass, body surface area and epirubicin kinetics. Anticancer Drugs 1994; 3: 293 – 297.
dc.identifier.citedreferencePfreundschuh M, Trumper L, Kloess M, et al. Two‐weekly or 3‐weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL‐B2 trial of the DSHNHL. Blood 2004; 104: 634 – 641.
dc.identifier.citedreferencePfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi‐weekly CHOP‐14 with or without rituximab in elderly patients with aggressive CD20 + B‐cell lymphomas: A randomised controlled trial (RICOVER‐60). Lancet Oncol 2008; 9: 105 – 116.
dc.identifier.citedreferenceCruz‐Jentoft A, Baeyens J, Bauer J, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412 – 423.
dc.identifier.citedreferenceMorton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265 – 276.
dc.identifier.citedreferenceSwerdlow S, Campo E, Harris N, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press; 2008.
dc.identifier.citedreferenceLanic H, Kraut‐tauzia J, Modzelewski R, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B‐cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 2014; 55: 817 – 823.
dc.identifier.citedreferenceNakamura N, Hara T, Shibata Y, et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B‐cell lymphoma. Ann Hematol 2015; 94: 2043 – 2053.
dc.identifier.citedreferenceGo S, Park MJ, Song H, et al. Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle 2016 DOI: 10.1002/jcsm.12115.
dc.identifier.citedreferenceCoiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‐B‐cell lymphoma. N Engl J Med 2002; 346: 235 – 242.
dc.identifier.citedreferenceEpelbaum R, Haim N, Ben‐Shahar M, et al. Dose‐intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 1988; 24: 533 – 538.
dc.identifier.citedreferenceKwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large‐cell lymphoma: Results of a tree‐structured survival analysis. J Clin Oncol 1990; 8: 963 – 977.
dc.identifier.citedreferenceLepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non‐Hodgkin’s lymphoma patients: Application to LNH‐87 protocol. Ann Oncol 1993; 4: 651 – 656.
dc.identifier.citedreferencePrado CMM, Baracos VE, Mccargar LJ, et al. Body composition as an independent determinant of 5‐fluorouracil‐based chemotherapy toxicity. Clin Cancer Res 2007; 13: 3264 – 3269.
dc.identifier.citedreferencePrado CMM, Baracos VE, Mccargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15: 2920 – 2926.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajh24465_am.pdf
Size:
679.8KB
Format:
PDF
View/Open
Name:
ajh24465.pdf
Size:
512.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.